Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cydan Is Launched For Rare Diseases
by Michael McCoy
April 22, 2013
| A version of this story appeared in
Volume 91, Issue 16
A new company, Cydan, has been formed to help accelerate the development of drugs for orphan diseases—diseases that affect fewer than 200,000 patients worldwide. Based in Cambridge, Mass., Cydan has raised $16 million in a financing round led by Pfizer Venture Investments and the venture capital firm New Enterprise Associates. Cydan says it will work with academic centers, patient foundations, and biotech companies to identify promising rare-disease programs. The most viable ones will be spun off from Cydan as start-up companies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter